In Los Angeles, endless immune cells take aim at cancer

Introduction: a promise born in a Los Angeles lab

A morning like any other at USC Stem Cell

Some discoveries don't make noise right away. They travel first through the quiet hallways of a university lab before ever reaching a headline. That's the case with work led by the team at USC Stem Cell, within the Keck School of Medicine at the University of Southern California, published in the journal Cell and picked up in late June 2026 by ScienceDaily. On paper, the subject sounds dry: precursor cells called GMPs, short for granulocyte-monocyte progenitors. But behind the acronym sits a simple, powerful idea: build a renewable reserve of immune cells that could, one day, be turned into weapons against cancer.

The lead researcher, Qi-Long Ying, professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC, describes a platform he considers scalable and tunable. In his view, this work lays down a scientific and technical foundation that could ripple well beyond oncology alone, potentially touching stem cell biology as a whole.

Why this discovery deserves your attention

Anyone who follows science news gets used to a weekly parade of miracle promises. Skepticism is a healthy reflex. But here, something is different: a precise laboratory method, published in a demanding peer-reviewed journal, backed by verifiable data on mice and human cells. This is not a cure. It's a technical building block — but one that could eventually make it easier to manufacture immunotherapy treatments at greater scale and lower cost.

This narrative will follow the thread of this research: how these cells were isolated, why their capacity for self-renewal changes the equation, what it concretely means for cancer patients, and above all, where today's certainties run out.

The starting problem: why current treatments run out of steam

Macrophages, an underused weapon

To understand what this research adds, you first need to revisit the role of macrophages. These immune cells serve on the front line of the body's defenses: they engulf and digest bacteria, viruses, and potentially cancer cells. For several years, the scientific community has been eyeing their potential as a therapeutic tool against cancer, alongside the famous CAR-T cells already used clinically for certain blood cancers.

The problem, documented by several recent clinical trials, is that the mature macrophages used in therapy burn out quickly once injected into the body. Their effect is real, but short-lived. That's the technical bottleneck Qi-Long Ying's team set out to break.

A reserve that runs dry too fast

Until now, producing macrophages or other specialized immune cells for therapy meant starting almost every time from a fresh source of stem cells or precursors. A costly, slow process, hard to standardize at scale. Without a stable, renewable source, it's difficult to imagine an off-the-shelf therapy, produced in advance and usable across many patients.

That's precisely what the researchers at USC set out to solve: how to keep precursor cells in culture for a long time, able to multiply without losing their identity or their capacity to become functional immune cells.

The discovery: cells that renew themselves

A chemical cocktail to slow maturation

The key to the discovery lies in a carefully defined cell culture method. Using a precise chemical cocktail, the team managed to stop GMPs from prematurely turning into other types of immune cells, while keeping them alive and multiplying over long stretches in the lab. The result: even after extended growth, these cells kept their original molecular and cellular characteristics, while continuing to generate functional macrophages and other immune cells.

What surprised the researchers most, according to their own statements relayed by ScienceDaily, is that these precursors, under certain conditions, behave almost like stem cells: they divide extensively while keeping their identity and their ability to produce functional immune cells.

A rare identity for progenitor cells

Traditionally, scientists did not attribute this self-renewal capacity to precursor cells like GMPs. That property was thought to belong to stem cells proper. The discovery that progenitors can also behave this way opens up, according to the researchers, new avenues both for cancer immunotherapy and for fundamental stem cell biology.

A molecular mechanism was also identified: the enzyme myeloperoxidase appears to act as a regulator of GMP proliferation, according to the scientific publication available on PubMed. It's this kind of mechanistic detail, often invisible in media summaries, that gives the whole body of work its solidity.

How these cells become an anti-cancer weapon

Adding a CAR receptor

Once the GMPs' capacity for expansion was demonstrated, the team moved to the next step: their genetic engineering. Researchers equipped these cells with a chimeric antigen receptor, better known by its acronym CAR, allowing the cells to recognize a specific marker present on cancer cells. It's the same logic that made CAR-T therapies famous, but applied here to a different cell family.

A second signal was also added, designed to activate surrounding immune cells and stimulate the T cells that fight tumors, reinforcing the body's natural defenses. Notably, this second signal remains effective even when donor and recipient cells are genetically mismatched, opening the door to therapies produced in advance from donor cells rather than custom-built treatments for each patient.

Off-the-shelf therapies?

This is where one of the most concrete hopes of this research lies: the possibility of creating standardized treatments, manufactured ahead of time and usable across multiple patients without requiring individualized production for each one. A potential paradigm shift compared with current cell therapies, whose extreme personalization is also what makes them so costly and slow to produce.

But careful: at this stage, these so-called allogeneic cells remain at the experimental stage. Nothing guarantees yet that they will behave the same way in humans as in the animal models tested so far.

The mouse results: solid tumors and blood cancers alike

A lasting foothold in the bone marrow

After being developed and modified, these cells were tested in mice, as well as with human cells cultured in the lab. The GMPs successfully settled into the bone marrow and other blood-producing tissues, where they kept generating, over the long term, modified macrophages and other immune cells. This point is crucial: because GMPs maintain a continuous supply of these cells from the bone marrow, they avoid the rapid depletion that had limited macrophage-based therapies until now, including those evaluated in recent clinical trials.

In mice bearing blood cancers and solid tumors, CAR-modified GMPs slowed disease progression. And GMPs carrying both the CAR and the additional immune signal produced even more pronounced benefits, according to the published data.

A benefit that reaches beyond cancer

Another striking result: GMP treatment also restored the animals' ability to fight bacterial infections, demonstrating the technology's potential for treating immune deficiencies, not just cancer. In the release relayed by ScienceDaily, the researchers explicitly mention cases of chronic granulomatous disease, a rare genetic condition that severely weakens antibacterial defenses.

This dual application — cancer and immunodeficiency — nicely illustrates the platform logic Qi-Long Ying describes: one base technology, several possible therapeutic doors.

Scientific context: a global race for renewable immune cells

USC isn't alone on this ground

It would be misleading to present this advance as an isolated one. Other teams are working, with different approaches, on similar problems. At UCLA, for instance, researchers published results in 2025 from an early clinical trial in which patients' blood stem cells were reprogrammed to continuously produce cancer-targeting T cells, an approach described by physician-researcher Theodore Scott Nowicki as a way of installing a permanent immune upgrade.

Meanwhile, the team of Ravi Majeti, director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, collaborated with USC's team and confirms, in a university statement, that it independently reproduced and maintained these genetically modified GMPs — additional validation of the result's robustness.

A convergence of leads, not a race

This landscape of parallel research deserves to be highlighted: this isn't one isolated lab announcing a miracle, but an entire scientific field converging, through different methods, on the idea of a renewable source of immune cells against cancer. It's this kind of convergence, more than any single announcement, that lends credibility to a research direction.

Majeti sums up the stakes this way: this method of expanding and engineering GMPs opens the door to numerous translational applications, much like what T cell expansion enabled a decade ago.

What this concretely changes for cancer patients

A horizon, not an available treatment

Let's be direct: at this stage, no patient can benefit from this technology. We're at the level of preclinical research — lab experiments and animal models — before any move to human clinical trials. The road between a publication in Cell and a therapy approved by health authorities is long, littered with regulatory, financial, and scientific obstacles.

But this kind of fundamental work is precisely what, years later, sometimes leads to approved treatments. CAR-T therapies, now used clinically against certain leukemias and lymphomas, were born from similar research — patient, unglamorous — more than a decade ago.

The economic weight of a standardized therapy

An aspect often overlooked in media coverage of these advances: cost. Personalized cell therapies, manufactured individually for each patient, are extraordinarily expensive — often several hundred thousand dollars per treatment. A platform like the one described by USC, should it one day lead to off-the-shelf products manufactured in advance, could potentially bring those costs down and widen access to this type of treatment.

It's a measured hope, but a hope nonetheless: an immunotherapy less reserved for the minority of patients with access to the best hospitals and the most generous insurance.

The methodological limits worth knowing

Mice, not humans

Nearly all of this study's most spectacular results, particularly the slowdown in tumor progression, come from mouse models. And the history of biomedical research is littered with treatments that worked brilliantly in mice before disappointing, or revealing unexpected side effects, in humans. That's not a reason to dismiss these results, but a reason to keep a sensible caution.

The human cells tested in the study were mostly tested in the lab, to check their behavior in culture and their expansion capacity, not as part of a clinical trial in living patients.

What the study doesn't say yet

No data yet exists on the long-term safety of these cells in humans, on possible side effects tied to their durable implantation in bone marrow, or on their real effectiveness against the diversity of human cancers, often far more heterogeneous than the standardized animal models used in the lab. Nor is there, at this stage, any official timeline for a human clinical trial of this specific technology.

It's this zone of uncertainty, honestly acknowledged by the researchers themselves in their publication, that should temper any excessive media enthusiasm.

The role of academic collaboration in this advance

A team effort across several institutions

This research did not emerge from an institutional vacuum. It results from a collaboration between Qi-Long Ying's lab at USC and that of Rong Lu, also at USC Stem Cell, with outside support from Ravi Majeti's lab at Stanford for independent validation. This multi-lab collaboration structure, common in cutting-edge science, reinforces the methodological credibility of the final result.

The funding and institutional support behind this kind of basic research, often coming from public funds or academic foundations, deserve to be remembered in a context where American biomedical research faces growing budget pressures.

A reminder about California's research ecosystem

California, and Los Angeles in particular, concentrates a significant share of American research on stem cells, largely thanks to organizations like the California Institute for Regenerative Medicine, which has funded similar work for years, including at UCLA. This institutional density partly explains why several converging advances on this topic emerge almost simultaneously in the same region.

This is not geographic coincidence, but the result of research investments accumulated over several decades.

Cancer immunotherapy: a field in full transformation

From CAR-T to modified macrophages

To place this discovery in its broader context, it helps to recall the path cancer immunotherapy has traveled over the past fifteen years. CAR-T therapies, which genetically modify a patient's own T cells to target their cancer cells, represented a revolution for certain blood cancers like leukemia and lymphoma. But they remain generally less effective against solid tumors, which make up the majority of cancers.

The growing interest in modified macrophages, of which this USC work is one example among others, stems partly from their natural ability to infiltrate solid tumor tissue, where T cells sometimes struggle to penetrate effectively.

HER2 as a tested target

According to the scientific publication available on PubMed, CAR-modified GMPs notably targeted the CD19 marker, used against leukemias, as well as the HER2 receptor, a well-known target in certain breast cancers, tested here on solid tumor models. The choice of these two targets — one for blood, one for solid tumors — illustrates the intent to demonstrate this platform's versatility.

It's this dual demonstration, blood and solid, that makes the study particularly interesting to the oncology research community.

How patients and advocacy groups view these advances

Cautious hope among patients

Without claiming to speak for cancer patients, it's fair to note that this kind of announcement resonates differently depending on where someone stands in their care journey. For some, every published advance fuels tangible hope. For others, further along in the disease, the time this research will take to reach the clinic can feel cruelly long.

Oncology patient advocacy groups regularly call for balanced communication about this kind of research: neither minimizing the scientific potential, nor promising imminent access that doesn't yet exist.

The role of responsible science communication

This is precisely the balance this narrative tries to strike: explaining what was discovered without exaggerating its immediate scope. Science communication carries a particular responsibility around subjects as sensitive as cancer, where miscalibrated hope can do as much harm as silence.

The role of science journalism is not to decide whether this discovery will change tomorrow's medicine, but to give the public the tools to understand what is proven, what is promising, and what remains uncertain.

The next steps expected in this field of research

Toward deeper preclinical trials

Before considering any clinical trial in humans, the USC team will likely need to deepen preclinical testing: verifying GMP stability over longer periods, testing their behavior against a broader diversity of tumor types, and above all, precisely documenting their safety profile in animal models physiologically closer to humans.

These steps generally take several years before a clinical trial application can be filed with regulatory authorities such as the Food and Drug Administration in the United States.

Funding still to secure

As with any biomedical research of this magnitude, the continuation of this work will depend largely on available funding, whether from federal grants, private foundations, or biotech investors. In an American context where federal research budgets face tense political debates, this variable is far from negligible.

Nothing guarantees, at this stage, a precise timeline for the continuation of this research program.

What this discovery says about the future of regenerative medicine

A blurred line between stem cells and immunity

This research fits into a broader trend in regenerative medicine: blurring the line between classic stem cells and specialized immune cells. For a long time, these two worlds were considered fairly separate. USC's GMPs show that an immune progenitor can, under certain conditions, adopt behavior close to that of a stem cell, redrawing the field's conceptual boundaries.

This porousness between biological categories isn't just an academic curiosity: it potentially opens the way to other similar discoveries in other families of progenitor cells, beyond the GMPs studied here by the team of Qi-Long Ying and Rong Lu.

A signal for biotech investment

Beyond academic circles, this kind of publication in a journal like Cell also draws the attention of the private sector. Biotech companies specializing in cellular immunotherapy closely watch these technological platforms, which could become, if they clear the clinical hurdle, the foundation of future commercial products. It's no accident that institutions like the California Institute for Regenerative Medicine actively fund this kind of exploratory work.

Still, the history of biotechnology is full of examples where promising preclinical results never reached the market, for lack of sufficient funding or conclusive clinical results. Caution remains warranted, even from a strictly economic standpoint.

Why this story deserves to be told now

A quiet victory for basic research

In a media landscape saturated with emergencies and crises, a discovery like this one — patient, methodical, carried by researchers who speak cautiously about their own work — deserves attention. It's a reminder that basic research, far from the spotlight, keeps moving forward, often invisible until the day it concretely changes a medical practice.

This narrative doesn't aim to celebrate a miracle that doesn't yet exist. It aims to tell, with its zones of certainty and uncertainty, one precise moment of science in the making.

The thread still to pull

It will be worth following, in the months and years ahead, whether this GMP platform clears the hurdle of human clinical trials. Only then will we be able to measure whether this laboratory promise translates into a real benefit for cancer patients.

Until then, caution and curiosity must remain this story's two compass points.

Conclusion: between scientific caution and legitimate hope

What we can say today

Researchers at USC Stem Cell have developed a method for multiplying, in the lab and over long periods, precursor immune cells called GMPs, while genetically modifying them to target cancer cells. The mouse results are encouraging, against both blood cancers and solid tumors, and suggest additional potential for treating certain immune deficiencies.

This advance fits into a broader movement in immunotherapy research, with comparable work carried out at UCLA and Stanford, which reinforces its overall scientific credibility.

What remains to be proven

No human clinical trial has yet begun for this specific technology. Long-term safety, real-world effectiveness against the diversity of human cancers, and the development timeline remain unknown. The hope is real, but it must stay measured, pending the next steps of this patient research.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I sign my pieces as Maxime Marquette, columnist for MadMax. I am neither a doctor nor a biologist; I rely on verifiable scientific publications and university press releases to make sense of complex medical news for a general audience. My acknowledged bias is to favor measured hope over systematic skepticism toward research advances, while categorically refusing any unproven promise of a cure.

I have no financial or professional ties to USC, Cell, or the laboratories cited in this narrative.

What I don't know, and my method

I cannot predict whether this technology will ever lead to an approved treatment for patients. No source available today allows for that. My method consists of cross-referencing the original scientific release, the corresponding academic publication where available, and independent university sources that collaborated on or commented on this work, in order to avoid any media exaggeration.

This text was written from open sources, cited in full in the following section, without privileged access to the researchers or a direct interview.

Sources

Primary sources

USC scientists just unlocked an endless supply of cancer-fighting immune cells — ScienceDaily, June 20, 2026

Advancing Cancer Immunotherapies — USC Stem Cell

Expansion and CAR engineering of granulocyte-monocyte progenitors — PubMed

Secondary sources

A New Route to Cancer Immunotherapy — Institute for Stem Cell Biology and Regenerative Medicine, Stanford, June 22, 2026

UCLA scientists reprogram stem cells to create renewable cancer-fighting immune cells — UCLA Health, July 31, 2025

New "Smart" Immune Cells: A Breakthrough for Long-Lasting Tumor Destruction — USC Viterbi